Ethicon builds women’s health business
This article was originally published in The Gray Sheet
Executive SummaryJohnson & Johnson/Ethicon completed its acquisition of uterine fibroid treatment developer Vascular Control Systems on May 9. Ethicon picks up Flostat, which is a minimally invasive alternative for uterine artery occlusion, and Cstat, a guided hemostat to control blood loss during open surgeries. On May 11, the J&J division announced it had received a CE mark for its female stress urinary incontinence treatment TVT Secur. The device, which can be implanted under local anesthesia, uses J&J's Prolene mesh to create a mid-urethral sling...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.